Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Surzebiclimab - BeOne Medicines

Next Previous
Drug Profile

Surzebiclimab - BeOne Medicines

Alternative Names: BGB-A425; Humanised IgG1-variant monoclonal antibody against TIM-3

Latest Information Update: 14 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BeiGene
  • Developer BeOne Medicines
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; HAVCR2 protein inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Solid tumours; Squamous cell cancer

Most Recent Events

  • 06 Feb 2025 BeiGene completes a phase I/II trial in in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) France, Italy, Poland, Spain, Australia, South Korea and in the US (IV) (NCT03744468)
  • 21 Jul 2023 Phase-II clinical trials in Squamous cell cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease, Recurrent) in USA, Australia, China (IV) (NCT05909904)
  • 21 Jul 2023 Phase-II clinical trials in Squamous cell cancer (First-line therapy, Metastatic disease, Late-stage disease, Recurrent, Combination therapy) in Taiwan (IV) (NCT05909904)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top